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Cytoskeleton nanomechanics characterizes cancer cell’s physical behaviors such as how it spread and invade. For anticancer drug, 
cytoskeleton nanomechanics may be a target to inhibit invasiveness and metastasis of cancer cells. Therefore, in vitro assay of 
cytoskeleton nanomechanics may be used to evaluate the effects of potential anticancer drug on various cancer types. Here, we 
investigated the effects of tubeimoside I (TBMS I) on human hepatoma (HepG2) cells by using optical magnetic twisting cytome-
try, a well-established technique for measuring nanomechanics of the F-actin cytoskeleton. TBMS I is a natural compound ex-
tracted from a traditional Chinese herbal medicine, and is reported with antitumor effect. In this study, we demonstrated that the 
cytoskeleton stiffness (G′) of HepG2 cells was affected by TBMS I. G′ exhibited a typical power law with respect to the loading 
frequency ( f ), i.e. G~f . The magnitude of G′ and the value of exponent () of the HepG2 cells decreased consistently with the 
increase of concentration for TBMS I exposure. In addition, the HepG2 cells responded to TBMS I much faster than the normal 
liver (L-02) cells. Such alteration of cytoskeleton nanomechanics induced by TBMS I was reported for the first time, which was 
further corroborated by assays of F-actin cytoskeleton structure and cell migration. Taken together, these results suggest that in 
vitro assay of cytoskeleton nanomechanics may have a great potential as an additional tool in screening of anticancer drug candi-
dates. 
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In the last two decades, tremendous advancements in both 
nanotechnology and photonic/optic technology have led to 
increasingly more innovative and versatile methods and 
devices for detection and measurement of physical and/or 
chemical events at micro/nanometer scales. One particularly 
important application of these developments is to the study 
of cytoskeleton nanomechanics that quantifies and charac-
terizes nanoscale mechanical properties/behaviors of the 
cytoskeleton in living cells. Because of the unprecedented 
spatial and temporal resolution of cytoskeleton nanome-
chanics, it has been widely recognized as the cutting edge 
tool in elucidating previously elusive mechanisms of intri-
cate biological processes in health and disease such as cell 
migration, cancer cell metastasis, and tissue morphogenesis.  
Less well recognized, however, is the potential for cyto-
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skeleton nanomechanics as a novel tool to investigate 
pharmacological action of drug in the living cell. For exam-
ple, change of cancer cell stiffness, a key feature of its cy-
toskeleton nanomechanics, can not only provide hints of the 
cancer’s malignancy and invasiveness, but may also be used 
to quantify the effect of a potential anticancer drug on the 
cancer cell’s behavior. Due to nanomechanical transduction 
of biochemical reactions, characterization of cytoskeleton 
nanomechanics allows sensitive, label-free, direct, real-time 
and multiplexed detection of molecules as well as specific 
investigations of molecular interactions and conformational 
changes within the living cells. Therefore, the approach of 
cytoskeleton nanomechanics can be a very valuable addition 
in the portfolio of drug screening techniques. 
Here, we investigate the effects of tubeimoside I, a natu-
ral plant extract and potential anticancer agent, on the cyto-
skeleton nanomechanics of human hepatoma (HepG2) cells 
in culture. Tubeimoside (TBMS), or the tuber of Bolbo-
stemma paniculatum (Maxim.) Franquet (Cucurbitaceae) is 
a herb that has long been used in traditional Chinese medi-
cine, and was listed in Supplement to the Compendium of 
Materia Medica published in early 1765 [1]. TBMS is most 
widely used for treatment of illness such as inflammation 
and snake venoms, but it has also been reported to show 
potent anti-tumor activity [2]. Such anti-tumor activity in 
part motivated the successful isolation of TBMS I, a 
triterpenoid saponin with chemical structure as shown in 
Figure 1 [3,4]. And subsequent studies confirmed that 
TBMS I can indeed inhibit growth of cultured cancer cells 
of several human cancer cell lines including human pro-
myelocytic leukemia (HL-60) [5], nasopharyngeal carcino-
ma CNE-2Z cell line (CNE-2Z) [6] and HeLa cells [7],  
 
 
Figure 1  The chemical structure of tubeimoside I. 
These studies appear to suggest that TBMS I may be a po-
tential candidate as a novel anti-tumor drug. 
Previous studies have identified that TBMS I targets 
cancer cells by altering the functions of microtubule [8], 
mitochondria [9] and endoplasmic reticulum [10], mostly 
through biochemical signaling pathways. It has, however, 
not been studied whether and how TBMS I may affect the 
cytoskeleton nanomechanics of cancer cells. Therefore, we 
evaluated TBMS I for its target on the nanomechanics of 
HepG2 cells, a well characterized human liver cancer cell 
type. We used optical magnetic twisting cytometry (OMTC), 
a well established method for cell nanomechanics, to meas-
ure the F-actin cytoskeleton stiffness of HepG2 cells in the 
absence or presence of TBMS I. In addition, we used 
Transwell® assay to examine the migration, and fluorescent 
microscopy to examine the F-actin cytoskeleton structure of 
HepG2 cells when exposed to TBMS I.  
Furthermore, the effects of TBMS I on HepG2 cells were 
compared to those on normal liver cells. Thus, we found 
that the cytoskeleton of HepG2 cells responded to TBMS I 
with depolymerization and reduced stiffness of the F-actin 
cytoskeleton, together with reduced migration rate. All 
these responses were greater and probably faster in HepG2 
cells than in normal liver cells, suggesting that TBMS I may 
be a drug candidate to specifically target cytoskeleton na-
nomechanics of HepG2 cells. 
1  Methods and materials 
1.1  Cell culture 
Human hepatocellular carcinoma cell line (HepG2) and 
normal liver cell line (L-02) were obtained from American 
Type Culture Center (ATCC, Manassas, VA, USA) and 
cultured in RPMI-1640 cell culture medium supplemented 
with 10% fetal bovine serum (FBS). TBMS I of different 
concentration was diluted by RPMI-1640 without FBS. 
Cultured cells were maintained in a humidified incubator at 
37°C in the presence of 5% CO2. The culture medium was 
changed every 2 days. Cells for assay were serum starved 
for 24 h before being tested and harvested by detachment 
with a solution of 0.25% trypsin and 0.02% EDTA.  
1.2  In vitro assay of cytoskeleton nanomechanics 
The cytoskeleton nanomechanics were assayed by optical 
magnetic twisting cytometry (OMTC), a well established 
method for measuring nanomechanical properties of F-actin 
cytoskeleton. The details of the OMTC technique are de-
scribed elsewhere [14,15]. In brief, cells (1×104 cells/well) 
were seeded in 96-well tissue culture plates which had been 
coated with collagen I (5 μg/mL) and cultured in RPMI- 
1640 growth medium supplemented with 10% fetal bovine 
serum for 24 h, then changed to serum-free RPMI-1640 for 
24 h. Subsequently, serum-free RPMI-1640 medium was 
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changed, then added the RGD-coated magnetic beads onto 
cells and waited for 20 min to allow the beads to bind to 
receptors on the cell surface. Soon after, the dish was 
mounted onto a microscope stage custom fitted with the 
bead twisting setup. The beads were magnetized horizon-
tally and then twisted in an oscillatory magnetic field. From 
the ratio of the applied magnetic torque to the measured 
lateral bead displacement, the complex elastic modulus was 
calculated and given as G′, that is elastic modulus, or stiff-
ness of the cytoskeleton, which has units of Pascal per na-
nometer as shown in Figure 2. 
For measuring the cytoskeleton stiffness versus frequen-
cy, the cells were treated with either sham or TBMS I at 10, 
20, 30 μmol/L, respectively, for 6 h. The F-actin stiffness 
was measured at frequency of 0.1, 0.3, 1, 5, 10, 30, 100 and 
300 Hz, respectively, run by proprietary software. 
For measuring the cytoskeleton stiffness versus time, the 
cell dish was mounted onto a microscope stage custom fit-
ted with the bead twisting setup. The beads were magnet-
ized horizontally and then twisted in an oscillatory magnetic 
field with a fixed frequency of 0.3 Hz, 60 cycles. Then 20 
μL of 525 μmol/L TBMS I was quickly added into the cell 
dish and the cytoskeleton stiffness was continuously meas-
ured up to 5 min. 
During each experiment, hundreds of cells with 171–556 
beads were measured simultaneously for F-actin stiffness 
(G′). Values of G′ measured by all the beads in one experi-
ment were pooled together, and the median of the pooled G′ 
was given as the cytoskeleton stiffness of each measurement. 
And for each experimental condition, the measurement of 
G′ was repeated 6–10 times. 
1.3  Structural assay of F-actin cytoskeleton 
The structure of F-actin cytoskeleton was assayed by fluo-
rescent microscopy. Cells (1×105 cells/well) were seeded on 
microscopic coverslips in the 96-well dish and then cultured 
in RPMI-1640 growth medium for 24 h. Thereafter the cells 
were treated with TBMS I at 10, 20, 30 μmol/L, respective-
ly, for 24 h. Cells treated with sham containing equal vol-
ume of cell culture medium but no TBMS I (0 μmol/L) were 
used as control in every experiment throughout this study. 
Subsequently the buffer was removed, and then cells were 
fixed with 4% formaldehyde in PBS for 20 min at room 
temperature. After washing three times with 1.5 mL PBS, 
cells were permeabilized with 1.5 mL 0.1% Triton-X-100 in 
PBS for 5 min and subsequently blocked with 1.5 mL 1% 
BSA in PBS for 20 min. F-actin filaments were then stained 
with 80 μL FITC-phalloidin (1:40 dilution of 200 μg/mL 
stock in DMSO, Enzo Life Sciences, USA) for 20 min at 
room temperature. After staining, the cells were washed 
three times with 1.5 mL PBS. The stained cells were visu-
alized with Leica TSP5 laser scanning confocal microscope 
(Leica Microsystems, Germany). 
1.4  In vitro assay of cell migration 
The migration activity of HepG2 cells was evaluated in 
vitro by using Transwell® chamber, a 24-well culture 
chamber with 8-μm pore size filter (Millipore, Billerica, 
MA). With each Transwell® chamber, the lower well was 
filled with RPMI-1640 cell culture medium containing 
TBMS I at either 0, 10, 20, or 30 μmol/L and supplemented 
with 20% fetal bovine serum. The upper well received 
1×104 cells in 200 μL RPMI-1640 cell culture medium con-
taining corresponding concentration of TBMS I (0, 10, 20, 
or 30 μmol/L, respectively). After incubation at 37°C for  
8 h, cells remained on the upper side of the filter were con-
sidered non-migrating and were carefully eliminated with a 
cotton swab. Cells that had migrated across the filter to the 
lower well were collected and stained with 0.1% crystal 
violet (0.5 g crystal violet was dissolved by 100 mL metha-
nol, then diluted with PBS of 4 times volume) for 30 min. 
The number of migrating cells collected from the lower well 
in each experiment was counted under optical microscope at 
100× magnification. Results were expressed as the average  
 
 
Figure 2  Illustration of optical magnetic twisting cytometry, as an in vitro assay of cytoskeleton nanomechanics. 
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number of migrating cells treated with TBMS I divided by 
the average number of migrating cells treated with sham. 
1.5  Materials and reagents 
Tubeimoside I was purchased from the National Institute for 
Control of Pharmaceutical and Biological Products (puri-
ty>98%, HPLC, Beijing, China). The 1 mmol/L stock solu-
tion of TBMS I was prepared in PBS and stored at −20°C. 
The stock solution was freshly diluted to the indicated con-
centrations with culture medium before use. Cell culture 
medium, RPMI-1640, and FBS were purchased from Bio-
logical Industries (Hyclone, USA), and Sijiqing Biological 
Engineering Materials Co., Ltd. (Hangzhou, China), colla-
gen I was purchased from Nutacon BV (Netherlands), 
Magnetic beads were kindly provided as a gift by Professor 
Jeffrey J Fredberg of Harvard School of Public Health, 
Boston, MA. Synthetic Arg–Gly–Asp (RGD) sequence pep-
tide was purchased from Peptite 2000 (Integra Life Sciences, 
Plainsboro Township, NJ, USA).  
1.6  Statistical analysis   
Except for the G′ measurement, each experiment was re-
peated three times, and the result was presented as mean ± 
standard deviation (SD). The results obtained under differ-
ent experimental conditions were evaluated using analysis 
of variance (ANOVA) followed by the Student’s t-test, and 
differences were considered statistically significant when 
P<0.05. 
2  Results 
2.1  Cytoskeleton stiffness  
The cytoskeleton stiffness of both the HepG2 cells and L-02 
cells were influenced by TBMS I as shown in Figures 3 and 
4, respectively. The effect of TBMS I was both frequency 
and time dependent. When measured at multiple frequencies, 
G′ exhibited power-law behavior in all cases, that is G′ in-
creased in proportion to the power of measurement fre-
quency, or G′∝f , where f is the frequency and  is the 
component of the power. However, the magnitude of G′ and 
the value of  were dependent on the treatment of TBMS I. 
Specifically, both the magnitude of G′ and the value of  
appeared to decrease when the cells were treated with 
TBMS I at increasing concentration for both L-02 cells and 
HepG2 cells. As the concentration of TBMS I increased 
from 0, to 10, 20, and 30 μmol/L, the value of  for L-02 
cells decreased from 0.1901, to 0.1285, 0.0933, and 0.0230, 
respectively (Figure 3(a)), while for HepG2 cells it de-
creased from 0.1983, to 0.1332, 0.0844, and 0.0145, respec-
tively (Figure 3(b)). 
When measured continuously at a fixed frequency but  
 
Figure 3  Relationship between measured G′ and the loading frequency, f 
displayed as log G′ vs. log f. (a) G′ measured in L-02 cells; (b) G′ measured 
in HepG2 cells. Symbols represent control condition (■, n=556), 10 μmol/L 
TBMS I (●, n=295), 20 μmol/L TBMS I (▲, n=239), and 30 μmol/L 
TBMS I (▼, n=171), respectively. 
prior and post to addition of TBMS I to the cells, both 
HepG2 and L-02 cells responded to the addition of TBMS I 
by quickly loosing stiffness of the cytoskeleton (Figures 4 
and 5). In HepG2 cells, the measured stiffness of the cyto-
skeleton was 0.44±0.01 Pa/nm prior to addition of TBMS I. 
Upon addition of 50 mol/L TBMS I, the stiffness was 
 
 
Figure 4  Time course of cytoskeleton stiffness in response to the addi-
tion of TBMS I. Symbols represent HepG2 cells, and L-02 cells, respec-
tively (■, n=324; ●, n=196). TBMS I was added at 50 mol/L. 
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Figure 5  Normalized time course of cytoskeleton stiffness in response to 
the addition of TBMS I Symbols represent HepG2 cells, and L-02 cells, 
respectively (■, n=324; ●, n=196). 
reduced to a minimal level (Figure 4). In L-02 cells, the 
stiffness (G′) measured prior to addition of TBMS I was a 
high 0.88±0.04 Pa/nm, which also quickly reduced to al-
most floor upon addition of TBMS I (Figure 4).  
Although both HepG2 and L-02 cells responded to 
TBMS I by reducing the cytoskeleton stiffness (G′), the 
speeds of their response were different. This difference is 
more obvious when the G′ was all normalized to its initial 
value measured at the beginning of the experiment (Figure 
5). It can be further demonstrated by the half time (T50) that 
is the time when G′ reduced to one half of its initial value 
between HepG2 and L-02 cells (73 vs. 109 s, P<0.05). 
2.2  F-actin cytoskeleton  
F-actin cytoskeleton of HepG2 cells appeared to be targeted 
by TBMS I. As shown in Figure 6(a), the HepG2 cells in the 
absence of TBMS I exhibited morphology of F-actin cyto-
skeleton that is normally seen with this type of cell. In con-
trast, in the presence of TBMS I, as the dose and exposure 
duration increased, the F-actin cytoskeleton in the cells ap-
peared to be increasingly thin, irregularly shaped, and dam-
aged along the edge of the cell. For example, after exposure 
to TBMS I for 24 h, the density of F-actin cytoskeleton in 
the cells treated with 10 μmol/L TBMS I appeared some-
what reduced with irregular shape as compared to control 
(Figure 6(b)), which was further reduced in cells treated 
with 20, and 30 μmol/L (Figure 6(c),(d)), indicating in-
creasing depolymerization of F-actin in these cells. 
 
 
Figure 6  Structures of F-actin cytoskeleton of HepG2 cells imaged by using fluorescence confocal microscopy. Representative images of F-actin cytoskel-
eton treated by either sham (0 μmol/L) are shown in (a), or TBMS I at 10 μmol/L in (b), 20 μmol/L in (c), 30 μmol/L in (d) (100× mag.). 
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2.3  Cell migration  
When HepG2 cells were treated with TBMS I for 8 h at 
increasing concentration (0, 10, 20 and 30 μmol/L), the cells 
became increasingly less able to migrate as demonstrated by 
fewer cells to have migrated through the filter of Transwell® 
chamber (Figure 7(a)–(d)). When compared to those treated 
with sham (the controls), the percentage of HepG2 cells that 
migrated through the filter of Transwell® chamber was 
59.3% at 10 μmol/L, 29.6% at 20 μmol/L and 3.7% at 30 
μmol/L, respectively (Figure 7(e)). 
3  Discussion  
The primary finding of this study is that exposure of HepG2 
cells to TBMS I at increasing concentration increasingly 
reduced the cytoskeleton stiffness (G′) and the value of ex-
ponent () for the power-law between the G′ and the load-
ing frequency (G~f ). In addition, while the F-actin cyto-
skeleton of HepG2 cells appeared to be softer than that of 
L-02 cells in the absence of TBMS I, the F-actin cytoskele-
ton of HepG2 cells responded much quickly than that of 
L-02 cells to the stimulation of TBMS I. This was the first 
time that the cytoskeleton nanomechanics of a type of can-
cer cell, HepG2 cells was studied with respect to the anti-
cancer effect of TBMS I as a potential drug candidate for 
cancer therapy. 
In addition to cytoskeleton stiffness, TBMS I also inhib-
ited migration of HepG2 cells. In parallel, the cells treated 
with TBMS I showed destruction and dissolution of the 
F-actin cytoskeleton labeled with FITC-Phalloidin. The 
results imply that TBMS I may target cancer cell’s F-actin 
cytoskeleton and eventually alter the physical behaviors 
associated with F-actin cytoskeleton structure such as can-
cer cell invasiveness. 
F-actin as a highly conservative protein, exists in the cy-
toplasm of all eukaryotic cells, and provides the primary 
structural component of the cytoskeleton. It is the most im-
portant determinant of cell mechanical properties/be-  
 
 
Figure 7  Cell migration assay for HepG2 cells using 
Transwell® chamber. Bright field images of cells 
migrated through the filter after being treated for 24 h 
with either sham (0 μmol/L) as shown in (a), or with 
TBMS I at 10 μmol/L as shown in (b), 20 μmol/L 
TBMS I as shown in (c), 30 μmol/L as shown in (d) 
(100× mag.). Quantitative results of cell migration for 
the above-listed experimental conditions are shown in 
(e). *P<0.05. 
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haviors. In response to extracellular signal stimulation, the 
F-actin cytoskeleton can change its structure and function 
rather swiftly via polymerization, depolymerization and 
rearrangement. It is now known that the F-actin cytoskele-
ton is not a static structure, instead, it is a very active and 
dynamic system. This system is constantly reorganizing 
itself in order to participate in and/or facilitate various im-
portant physiological activities such as division, migration, 
maintenance of cell shape and bearing external force 
[11–13]. 
Because RGD could bind to the F-actin cytoskeleton 
through the integrin receptor within the focal adhesions in 
the cell membrane, the stiffness measured by OMTC meth-
od directly reflects the mechanical properties of the F-actin 
cytoskeleton. OMTC employs magnetic manipulation and 
optical detection/quantification in an integrated system to 
allow a non-invasive method to assess the nanomechanics 
of cells. Using this method, hundred cells can be simulta-
neously assessed in one experiment. The fast response of 
cytoskeleton nanomechanics to drug agent is another ad-
vantage. These suggest that the method may have a great 
potential to be developed as a high throughput and rapid 
tool for drug screening. 
The measured cytoskeleton stiffness of HepG2 and L-02 
cells exhibited power-law behavior with regards the loading 
frequency, which is consistent with reports by Fabry et al. 
[16]. The value of exponent () for the power-law between 
the stiffness and the loading frequency (G~f ) reflects the 
state and tendency of fluidization for the cells. When  = 0, 
it is pure solid; =1, it is pure Newtonian fluid; 0 < <1, it 
is between solid and fluid, and at this time  determines the 
tendency of being solid or liquid [16]. The measured results 
show that the stiffness of HepG2 cells was smaller than that 
of L-02 cells in the absence of TBMS I. The value of  for 
HepG2 cells was, however, greater than that for L-02 cells. 
This suggests that the HepG2 cell is not only softer, but 
importantly more fluid-like than the L-02 cells. These na-
nomechanical behaviors are nevertheless consistent with the 
fact that the HepG2 cell is a cancer cell type that is charac-
terized by greater ability to migrate and deform, all require 
the cells to be fluid. When TBMS I was in presence, both 
the stiffness and the value of  were reduced in all cases. 
The time course of measured G′ also shows a prompt de-
cline when TBMS I was added at a time point between 50 to 
80 seconds. The degree of stiffness reduction in HepG2 
cells was greater than that of L-02 cells. These results show 
that TBMS I may not only target F-actin cytoskeleton, but 
also selectively cause greater and faster changes of the 
F-actin cytoskeleton in cancerous cells such as HepG2 cells 
than in normal cells such as L-02 cells. 
Changing mechanical properties of the cancer cells can 
also alter the cancer cells’ interaction with their microenvi-
ronment, leading to either promotion or inhibition of cancer 
cell invasion and metastasis [17]. Therefore, it is necessary 
to elucidate the role of cancer cell cytoskeleton nanome-
chanics in regulating cancer cell growth and metastasis with 
or without anticancer drug intervention. Our finding that 
TBMS I caused destruction and dissolution of F-actin cyto-
skeleton, and corresponding decrease of the cytoskeleton 
stiffness and fluidity imply that cancer cells (HepG2) may 
be affected by anticancer drug (TBMS I) in a way to dys-
function in active motility and deformation. Thus, in vitro 
assay of the cytoskeleton nanomechanics of the cancer cells 
becomes necessary to properly reflect the pharmacological 
action of anticancer drug agent, TBMS I on the working of 
the F-actin cytoskeleton of HepG2 as a physical pathway to 
inhibit invasion and metastasis of the cancer cells. This 
pathway is an important supplement to the molecular path-
ways of TBMS I in HepG2 cells including apoptosis as re-
ported by Wang et al. [18,19]. 
It should be noted that the present study is limited to cells 
from one cancer type. Cells from other types of cancer in-
cluding breast cancer, lung cancer and pancreas cancer have 
been examined for their nanomechanics by different tech-
niques such as atomic force microscopy [20,21]. The results 
reported by those studies are, in general, consistent with our 
findings despite the differences in cancer types and meas-
urement methods employed. Nevertheless, it is indeed nec-
essary to further test other cancer types in regards their na-
nomechanics response to the administration of anticancer 
drug. In addition, it is likely that the anticancer drug such as 
TBMS I targets cytoskeleton nanomechanics via multiple 
pathways apart from the F-actin structure. For instance, the 
myosin light chain (MLC) in cancer cells may well be af-
fected by anticancer drug, which would change the state of 
intracellular tension and ultimately contribute to altering 
cytoskeleton nanomechanics. Further studies are required to 
fully elucidate the mechanisms that mediate the drug-  
induced changes in cytoskeleton nanomechanics. 
Taken together, we conclude that in vitro assay of cyto-
skeleton nanomechanics could be used as a novel tool in 
drug screening in addition to other conventional tools. Us-
ing this method, we confirmed that TBMS I was a potent 
agent to target cytoskeleton stiffness and fluidization of 
hepatoma (HepG2) cells. The pharmacological effects were 
mediated by suppression of the cells’ motility via dismantling 
the F-actin cytoskeleton structure. Furthermore, the differ-
ence in response speed of cytoskeleton stiffness between 
HepG2 cells and L-02 cells, to the stimulation of TBMS I, 
suggests a certain specificity of targeting cytoskeleton nano-
mechanics by the anticancer drug. This was a novel finding 
of the role of TBMS I in regulation of cancer cell structure 
and function, providing a supplemental mechanism of cyto-
toxicity and drug sensitivity for TBMS I. Considering its 
preferential distribution in the liver and its origin of natural 
medicinal plant, this study suggests that TBMS I may be a 
useful drug candidate for treating liver cancer.
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